Literature DB >> 26541309

Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.

Doh Young Lee1, Jae-Kyung Won2, Se-Hoon Lee3, Do Joon Park4, Kyeong Cheon Jung2, Myung-Whun Sung5, Hong-Gyun Wu6, Kwang Hyun Kim5, Young Joo Park4, J Hun Hah5.   

Abstract

BACKGROUND: This study aimed to analyze the temporal changes of the clinicopathologic characteristics, and the long-term outcomes, of various types of anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer (PDTC).
METHODS: A retrospective analysis was conducted on patients with ATC and PDTC who were treated from 1985 to 2013. The outcome measures included the clinical response to treatment and the survival rates of three separate thyroid cancer groups: ATC, PDTC, and differentiated thyroid cancer (DTC) with anaplastic foci.
RESULTS: The five-year disease-specific survival rate was significantly higher, both in DTC with anaplastic foci and in PTDC (81.3% and 65.8%, respectively), than it was in ATC (14.3%; p < 0.001). The proportion of cases of DTC with anaplastic foci has been increasing over time, while that of ATC has decreased. The survival rate was found to be significantly higher in resectable tumors (71.4% and 26.5%, respectively; p < 0 .001). In ATC, external beam radiation therapy showed longer survival rates than did surgery-based treatment in unresectable tumors (19.2 vs. 7.7 months, p = 0.006). Adjuvant treatment with external beam radiation or radioactive iodine increased survival duration in PDTC and in DTC with anaplastic foci. Lymphatic invasion was the most significant postoperative prognosticator in ATC (p = 0.013).
CONCLUSIONS: The choice of treatment of ATC and PDTC could be modified according to resectability and lymphatic invasion of the cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26541309     DOI: 10.1089/thy.2015.0316

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  17 in total

1.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

Review 2.  Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.

Authors:  Cristina Pizzimenti; Vincenzo Fiorentino; Antonio Ieni; Maurizio Martini; Giovanni Tuccari; Maria Lentini; Guido Fadda
Journal:  Endocrine       Date:  2022-07-21       Impact factor: 3.925

3.  Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.

Authors:  Dmytro Oliinyk; Teresa Augustin; Josefine Rauch; Viktoria Florentine Koehler; Claus Belka; Christine Spitzweg; Lukas Käsmann
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-12       Impact factor: 4.322

Review 4.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

Review 5.  Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.

Authors:  Daniel A Ladin; Eman Soliman; LaToya Griffin; Rukiyah Van Dross
Journal:  Front Pharmacol       Date:  2016-10-07       Impact factor: 5.810

6.  Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases.

Authors:  Tian-Run Liu; Zhi-Wen Xiao; Hai-Neng Xu; Zhen Long; Fan-Qin Wei; Shi-Min Zhuang; Xiao-Mei Sun; Liang-En Xie; Jia-Sheng Mu; An-Kui Yang; Guan-Ping Zhang; Yi Fan
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

7.  Application of intensity-modulated radiotherapy in unresectable poorly differentiated thyroid carcinoma.

Authors:  Fen Xue; Duanshu Li; Chaosu Hu; Zhuoying Wang; Xiayun He; Yi Wu
Journal:  Oncotarget       Date:  2017-02-28

8.  TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.

Authors:  Francesca Maria Orlandella; Gennaro Di Maro; Clara Ugolini; Fulvio Basolo; Giuliana Salvatore
Journal:  Oncotarget       Date:  2016-10-25

9.  Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC.

Authors:  Ben Ma; Weibo Xu; Wenjun Wei; Duo Wen; Zhongwu Lu; Shuwen Yang; Tongzhen Chen; Yulong Wang; Yu Wang; Qinghai Ji
Journal:  Int J Endocrinol       Date:  2018-05-21       Impact factor: 3.257

10.  Dietary iodine intake, therapy with radioiodine, and anaplastic thyroid carcinoma.

Authors:  Nikola Besic; Barbara Gazic
Journal:  Radiol Oncol       Date:  2020-05-02       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.